This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 4 of 16 for:    cancer | Studies received from 04/21/2016 to 04/21/2016

Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers

This study is currently recruiting participants.
See Contacts and Locations
Verified June 2017 by Alliance for Clinical Trials in Oncology
Sponsor:
Collaborators:
National Cancer Institute (NCI)
Astellas Pharma US, Inc.
Information provided by (Responsible Party):
Alliance for Clinical Trials in Oncology
ClinicalTrials.gov Identifier:
NCT02749903
First received: April 21, 2016
Last updated: June 20, 2017
Last verified: June 2017
  Purpose
This study will test any good and bad effects of the study drug called enzalutamide. Enzalutamide could shrink the cancer but it could also cause side effects. Researchers hope to learn if the study drug will shrink the cancer by at least 30% compared to its present size, in at least 1 out of 5 patients. Enzalutamide is not FDA approved to treat salivary gland cancer, but it has already been FDA-approved to treat other cancers.

Condition Intervention Phase
Salivary Cancer Drug: enzalutamide Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Phase II Study of Enzalutamide (NSC# 766085) for Patients With Androgen Receptor Positive Salivary Cancers

Resource links provided by NLM:


Further study details as provided by Alliance for Clinical Trials in Oncology:

Primary Outcome Measures:
  • best overall response rate [ Time Frame: Up to 32 weeks ]

Secondary Outcome Measures:
  • progression-free survival [ Time Frame: Up to 3 years post study enrollment ]
  • adverse events (The maximum grade for each type of adverse event will be summarized using CTCAE version 4.0.) [ Time Frame: Up to 3 years post study enrollment ]
  • adverse events (The frequency and percentage of grade 3+ adverse events will be summarized using CTCAE version 4.0.) [ Time Frame: Up to 3 years post study enrollment ]

Estimated Enrollment: 45
Study Start Date: June 2016
Estimated Primary Completion Date: April 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Enzalutamide
Patients receive 160 mg enzalutamide orally once daily (1 cycle=28 days). Patients will remain on therapy until progression of disease or development of unacceptable toxicities or patient or physician withdrawal. Patients will undergo radiographic imaging every 2 months while on study treatment in order to determine response.
Drug: enzalutamide
oral

Detailed Description:

This single arm Phase II trial will assess the best overall response associated with enzalutamide in patients with AR-positive salivary cancers. Given that this will be one of the first prospective studies ever conducted for AR-positive salivary cancers, and there are currently no standard therapies known to be effective for this disease, the investigators will adopt a best overall response (BOR) of 5% as the null hypothesis and BOR of 20 % as the alternative hypothesis. In addition to response, this study will also evaluate the progression-free survival (PFS), overall survival (OS), adverse events, and will also try to identify molecular predictors of response by examining genomic and transcriptional elements of androgen receptor biology.

The primary and secondary objectives of the study:

Primary objective

To evaluate the rate of best overall response associated with enzalutamide in patients with AR-positive salivary cancers

Secondary objectives

  1. To evaluate the progression-free survival (PFS) of AR-positive salivary cancer patients treated with enzalutamide
  2. To evaluate the overall survival (OS) of AR-positive salivary cancer patients treated with enzalutamide
  3. To evaluate the safety/tolerability of enzalutamide for patients with AR-positive salivary cancer

Patients are followed up to 3 years after study enrollment.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  1. Documentation of Disease - Histologic Documentation: Histologically proven diagnosis of salivary cancer by central pathology review. Receptor status: AR expression detected by immunohistochemistry by central review.
  2. Disease status - Measurable disease as defined in the protocol. Locally advanced/unresectable (as determined by local surgeon) OR metastatic disease.
  3. Prior Treatment

    • Any number of prior lines of therapy
    • No treatment with biologic therapy, immunotherapy, chemotherapy, investigational agent for malignancy, or radiation ≤ 28 days before study registration. No treatment with nitrosourea or mitomycin ≤ 42 days before study registration
    • No prior therapy with enzalutamide (previous chemotherapy and/or other AR-targeted approaches is allowed).
  4. Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects. A female of childbearing potent is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 12 consecutive months (ie, has had menses at any time in the preceding 12 consecutive months). For women of childbearing potential only, a negative pregnancy test done ≤ 5 days prior to registration is required.
  5. Age ≥ 18 years
  6. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
  7. No History of the following:

    • prior brain metastases
    • leptomeningeal disease
    • seizures
    • class 3 or 4 congestive heart failure
    • uncontrolled hypertension (systolic BP > 170 mmHg or diastolic BP > 105 mmHg)
    • major surgery ≤ 4 weeks of registration
  8. Required Initial Laboratory Values:

    • Absolute Neutrophil Count (ANC) ≥ 1,500/mm3
    • Platelet Count ≥ 100,000/mm3
    • Creatinine ≤ 1.5 x ULN Upper Limit of Normal (ULN) OR
    • Calculated Creatinine Clearance ≥ 30 mL/min
    • Total Bilirubin ≤ 1.5 x ULN
    • AST/ALT ≤ 3.0 x ULN
  9. Concomitant medications- Chronic concomitant treatment with strong CYP2C8 inhibitors is not allowed. Patients must discontinue the drug ≥ 14 days prior to registration. Chronic concomitant treatment with strong CYP3A4 inducers is not allowed. Patients must discontinue the drug ≥ 14 days prior to registration.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02749903

Contacts
Contact: Alan Ho, MD, PhD 646-888-4235

  Show 257 Study Locations
Sponsors and Collaborators
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)
Astellas Pharma US, Inc.
Investigators
Study Chair: Alan Ho, MD Memorial Sloan Kettering Cancer Center
  More Information

Responsible Party: Alliance for Clinical Trials in Oncology
ClinicalTrials.gov Identifier: NCT02749903     History of Changes
Other Study ID Numbers: A091404
NCI-2015-01706 ( Registry Identifier: NCI Clinical Trial Reporting Program )
Study First Received: April 21, 2016
Last Updated: June 20, 2017

Additional relevant MeSH terms:
Androgens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on June 23, 2017